Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial.

Publication

Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial.

Journal Paper/Review - May 3, 2021

Müllhaupt Gautier, Güsewell Sabine, Schmid Hans-Peter, Zumstein Valentin, Betschart Patrick, Engeler Daniel, Abt Dominik

Citation

Müllhaupt G, Güsewell S, Schmid H, Zumstein V, Betschart P, Engeler D, Abt D. Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial. BMJ Open 2021; 11:e046973.

Type

Journal Paper/Review (English)

Journal

BMJ Open 2021; 11

Publication Date

May 3, 2021

Issn Electronic

2044-6055

Pages

e046973

Brief description/objective

A novel method for the surgical treatment of benign prostatic hyperplasia (BPH) called Aquablation has become commercially available. Previous studies have been able to show similar functional results when compared with transurethral resection of the prostate and a high efficacy has been demonstrated when this approach is applied to patients with a prostate size of 80-150 cm.Holmium laser enucleation of the prostate (HoLEP) is a well-established procedure in the surgical treatment of BPH in prostate glands larger than 30 mL and a first-line therapy in glands over 80 mL. To date, no data are available whether Aquablation is non-inferior compared with HoLEP in the treatment of patients with medium-to-large-sized prostates regarding safety and efficacy.